Erdheim-Chester disease

Last revised by Rohit Sharma on 3 Nov 2024

Erdheim-Chester disease (ECD) is a rare non-Langerhans cell, non-familial multisystemic histiocytosis, with widespread manifestations and of highly variable severity.

Erdheim-Chester disease is a rare, non-inherited disease of middle age with a slight male predominance 6.

Patients may present with a variety of symptoms, ranging from focal neurological deficits to multiorgan failure 5. The most common presenting symptom is bone pain. However, patients may also present with focal neurological deficits, exophthalmos, retroperitoneal fibrosis, diabetes insipidus, and dyspnoea due to the variably extensive extraskeletal involvement of the disease.

Erdheim-Chester disease is a systemic lipogranulomatous disorder with infiltration by lipid-laden histiocytes (foamy macrophages), Touton giant cells, and a variable amount of background fibrosis 2. In contrast to Langerhans cell histiocytosis (LCH), no S-100 nor CD1 are detected 1, but CD68 is positive 10. It is associated with BRAF V600E mutations 14-16.

Both Erdheim-Chester disease and Langerhans cell histiocytosis (LCH) may coexist, and cases of double infiltration have been reported 10

Musculoskeletal involvement is most common, with multifocal extraskeletal involvement seen in 30-50% of patients 1,2.

  • bilateral, symmetric metaphyseal and diaphyseal sclerosis 1,2

  • increased uptake on Tc-MDP bone scan 7

  • cortical thickening

Intracranial involvement of the dura, brain and pituitary are rare 3:

  • meninges

    • dural accumulations may mimic meningiomas, with enhancing soft tissue masses

    • T2 signal characteristics are somewhat different, as the accumulations in Erdheim-Chester disease are hypointense 3

  • brain

    • most commonly affecting the pons and cerebellum 14

    • can also affect the hypothalamus 3,14

    • intraparenchymal masses appear non-specific 10

  • pituitary infundibulum 14: presenting with diabetes insipidus

Corticosteroids, radiotherapy and chemotherapy have all been used but with little effect, with some patients relentlessly progressing 1. In patients with BRAF V600-mutant Erdheim-Chester disease, BRAF inhibitors, such as vemurafenib, can be effective 15,16. Surgical or percutaneous intervention for hydronephrosis, orbital or meningeal involvement is useful for symptomatic local disease.

Pulmonary fibrosis and cardiac failure are the most common causes of death 2. Given the small volume of published data, mortality rates are unclear but may be as high as 60% 2.

It was first described in 1930 as "lipid granulomatosis" by Jakob Erdheim (1874-1937), an Austrian pathologist, and William Chester (1903–1974), an American pathologist 9,12.

The differential diagnosis for Erdheim-Chester disease is very dependent on location although some entities will be considerations in most locations (e.g. lymphoma).

The differential for intracranial involvement is that of other causes of dural masses including: 

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.